Hyaluronidase Market Size, Share, Trends, Growth 2030

Hyaluronidase Industry Perspective:

The global hyaluronidase market size is set for rapid growth over the forecast period. In terms of revenue, the global hyaluronidase market accounted for USD 863.12 Million in 2022 and is expected to reach USD 1,326.9 Million by 2030, growing at a CAGR of 9.01% during the forecast period.

The market report offers quantitative and qualitative insights into the key drivers, opportunities, constraints, and challenges impacting global hyaluronidase industry growth.

Request Free Sample

Hyaluronidase Market: Overview

Hyaluronic acid, also referred to as hyaluronan, is a clear, gooey material that your body naturally produces. Hyaluronic acid is found all over the body in conjunctive tissue, skin, the eye, and fluids in the joints. It allows fluids to have a texture similar to glue, which may help to moisten tissues & joints and secure them. In medicine, hyaluronidase is produced in the laboratory and given by injection under the skin with other medicines to treat certain conditions. The use of hyaluronidase to break down hyaluronic acid helps to thin out the fluids and connective tissue so that the medicines can pass into the tissues more easily.

In clinical practice, hyaluronidase use has become more broad and common. It is used, in particular, to resolve the discomfort of patients following treatment with hyaluronic acid filler and to treat side effects. It is increasingly necessary for clinicians to have adequate knowledge of hyaluronidase as its use becomes more widespread. If it is used with a comprehensive understanding of its modes of action, side effects, and metabolism, hyaluronidase can serve as an effective therapy in a variety of situations.

Key Insights

• As per the analysis shared by our research analyst, the global hyaluronidase market is expected to grow annually at a promising CAGR of around 9.01% during the forecast period 2023-2030.
• In terms of revenue, the global hyaluronidase market size was valued at around USD 863.12 million in 2022 and is expected to reach USD 1,326.9 million by 2030.
• Based on type, the animal-derived hyaluronidase segment held the dominating market share in 2022.
• Based on application, the dermatology segment held a notable market share in 2022
• Based on region, the North American region held the largest market share in 2022.

Request Free Sample

Hyaluronidase Market: Growth Factors

Increasing application in cosmetics, pharmaceuticals to boost the global market growth

Hyaluronidase is used in cosmetic therapies, cancer treatments, and ophthalmic medicinal solutions. Due to the use of enzyme-based substrates for non-invasive disease diagnosis, and its evolving position in cancer metastasis & treatment is expected to drive demand and subsequent market growth across profitable avenues.

In addition, the growing understanding of physical appearance alterations has resulted in an increasing number of cosmetics and aesthetic treatments. Demand for hyaluronidase in cosmetic dermatology is growing, driven primarily by an increased incidence of skin disorders and easy access in different regions to modern cosmetic treatments.

Increasing geriatric demographics, favorable reimbursement policies, and a number of people opting for cosmetic nonsurgical procedures are other factors responsible for the projected hyaluronidase industry development. Hyaluronidase therapy can resolve fillers injected in high amounts and may also help dissolve subcutaneous nodules. This has intensified the interest of cosmetic industry practitioners in acquiring awareness of the use, working principle, and harmful impacts of this enzyme.

Therefore, the therapist should be well-versed in the correct dosage of hyaluronidase along with any complications and remedies that may be required. Rising developments targeted at decreasing the side effects of hyaluronidase administration are anticipated to fuel the growth of companies operating in the global hyaluronidase market.

Hyaluronidase Market: Restraints

Extortionate cost of treatment and lack of skilled professionals might impede the growth of the industry

The global hyaluronidase market is expected to face challenges such as the high cost of treatment, adverse side effects, and strict regulations regarding the use of hyaluronidase. In addition, the limited availability of skilled professionals and the risk of infections associated with the use of hyaluronidase are further predicted to hinder the growth of the market during the forecast period.

Hyaluronidase Market: Opportunities

Surge in demand for minimally-invasive surgeries and development of biosimilars create ample opportunities for the industry

The global hyaluronidase industry is expected to see significant growth in the coming years due to the rising prevalence of chronic diseases, increasing demand for minimally invasive surgeries, and growing awareness about hyaluronidase applications in the pharmaceutical & cosmetic industries. The market is expected to be driven by the use of hyaluronidase in the treatment of cancer, surgical procedures, and ophthalmology. The market growth is also supported by technological advancements in drug delivery systems and the availability of funding for research & development activities. Furthermore, the increasing adoption of hyaluronidase in developing countries and the development of biosimilars are expected to create new growth opportunities for the market in the future.

Hyaluronidase Market: Challenges

Risk of allergic reactions and stringent regulations on the use of hyaluronidase act as a challenge for the industry

The risk of adverse side effects associated with hyaluronidase may also limit its widespread use. Although hyaluronidase is generally considered safe, there is a risk of allergic reactions, including anaphylaxis, in some patients. Strict regulations regarding the use of hyaluronidase may also pose a challenge to the hyaluronidase industry growth. The regulatory landscape for hyaluronidase varies across countries, and some countries have stringent regulations for its use. This may limit its availability and adoption in some markets.

Hyaluronidase Market: Segmentation

The global hyaluronidase market is segmented into type, application, and region.

Based on type, the market is bifurcated into animal-derived hyaluronidase and synthetic hyaluronidase. The animal-derived hyaluronidase segment held the largest market share in 2022 and is further predicted to cite a notable CAGR during the forecast period. The animal-derived hyaluronidase segment of the market is expected to experience steady growth due to the increasing demand for hyaluronidase in animal husbandry and veterinary medicine. Animal-derived hyaluronidase is commonly used to improve the effectiveness of vaccines, particularly in poultry and swine industries, and as a wound-healing agent in veterinary medicine.

In addition, animal-derived hyaluronidase is used in various research and development activities in the pharmaceutical and biotechnology industries. The animal-derived hyaluronidase segment is also expected to benefit from the growing trend toward the use of natural and organic products in the cosmetic industry. Animal-derived hyaluronidase is used as an ingredient in skincare products, particularly in anti-aging products, due to its ability to stimulate collagen production and improve skin hydration.

Based on application, the market is segmented into chemotherapy, dermatology, ophthalmology, plastic surgery, and others. The dermatology segment held a dominating market share in 2022 and is further projected to cite a notable CAGR during the forecast period. The dermatology segment of the hyaluronidase market is expected to experience significant growth due to the rising demand for injectable dermal fillers and the increasing popularity of minimally invasive cosmetic procedures.

Hyaluronidase is used in dermatology to quickly dissolve hyaluronic acid-based dermal fillers, which are commonly used to treat wrinkles, fine lines, and volume loss. The increasing prevalence of skin-related conditions, such as acne and rosacea, is also expected to drive the demand for hyaluronidase in dermatology. Hyaluronidase is used as a treatment for these conditions, as it can help to reduce inflammation and promote wound healing. The dermatology segment is expected to benefit from the growing trend toward natural and organic skincare products. Hyaluronidase is increasingly being used as an ingredient in these products, as it has been shown to stimulate collagen production and improve skin hydration.

Recent Developments

• In August 2021, Halozyme Therapeutics, Inc. announced the initiation of Phase 3 clinical trial for its investigational drug, PEGPH20, in combination with chemotherapy in patients with previously untreated metastatic pancreatic cancer. PEGPH20 is a pegylated recombinant human hyaluronidase that targets the extracellular matrix of tumors to improve the delivery of chemotherapy.
• In July 2021, Shire, a subsidiary of Takeda Pharmaceutical Company Limited, received FDA approval for its investigational enzyme replacement therapy, HyQvia, for the treatment of primary immunodeficiency. HyQvia contains recombinant human hyaluronidase and is administered subcutaneously to improve the absorption and distribution of immunoglobulin.
• In June 2021, Abbott announced the launch of its Alinity m system, a molecular diagnostic instrument that offers a broad range of infectious disease testing capabilities. The instrument features the company's proprietary hyaluronidase pretreatment technology, which is designed to enhance the extraction of DNA and RNA from samples.

Hyaluronidase Market: Report Scope

Hyaluronidase Market: Regional Analysis

North America to lead the global market in the coming period

Based on region, the North American region held the largest market share in 2022 and is further predicted to grow rapidly at a significant CAGR during the forecast period. This is mainly due to the increasing demand for hyaluronidase in various medical and cosmetic applications. The rising prevalence of skin-related conditions such as acne, rosacea, and wrinkles has resulted in the increased adoption of hyaluronidase in dermatology. Moreover, the growing geriatric population in North America is also expected to drive the demand for hyaluronidase, particularly in the treatment of age-related conditions such as osteoarthritis.

The increasing prevalence of chronic diseases such as cancer and diabetes is also expected to boost the demand for hyaluronidase as an adjuvant therapy to improve drug delivery. North America is a prominent market for cosmetic procedures, and hyaluronidase is increasingly being used as a treatment for overfilled areas or unwanted lumps resulting from dermal filler injections. The availability of advanced healthcare infrastructure, higher disposable income, and the presence of key market players in the region are some of the factors contributing to the growth of the hyaluronidase market in North America.

Asia Pacific is predicted to see the highest growth in the hyaluronidase market in the near future as a result of medical tourism for dermatology and chemotherapy applications in various countries. This has facilitated investments in the Asia Pacific by many foreign companies. The presence of a large number of manufacturers, combined with the advent of technology in South Korea, is an opportunity to push the Asian market at a lucrative rate. After China, South Korea is second in terms of revenue production in the Asian market. In July 2018, Alteogen created the world's second-largest recombinant human hyaluronidase protein and proprietary protein engineering technology.

Hyaluronidase Market: Competitive Landscape

The global hyaluronidase market is dominated by players such as:

• Baxter International Inc.
• Halozyme Therapeutics Inc.
• Pfizer Inc.
• Shire Plc
• F. Hoffmann-La Roche Ltd.
• Sandoz International GmbH
• Quidel Corporation
• CSL Limited
• Pharming Group NV
• IBSA Institut Biochimique SA
• Fresenius Kabi AG
• Johnson & Johnson
• Nordic Group BV
• Bausch Health Companies Inc.
• AstraZeneca
• Merck KGaA
• Teva Pharmaceutical Industries Ltd.
• Santen Pharmaceutical Co. Ltd.
• Sanofi SA.

Global Hyaluronidase Market is segmented based on:

By Type

• Animal-Derived Hyaluronidase
• Synthetic Hyaluronidase

By Application

• Chemotherapy
• Dermatology
• Ophthalmology
• Plastic Surgery

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa